Short communication (Scientific journals)
Personalising metformin therapy: a clinician's perspective
SCHEEN, André
2014In The Lancet Diabetes and Endocrinology
Peer Reviewed verified by ORBi
 

Files


Full Text
TXT Comment Metformin genetics Lancet Diabetes Endocrinol Final 2014.pdf
Author postprint (181.67 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] If lifestyle changes are not effective for maintaining glycaemic control, metformin is recommended as the first glucose-lowering drug to use in a patient with type 2 diabetes, if the patient has no contraindications—eg, renal impairment or hypoxic disorders.1 However, the glucose-lowering response to metformin can vary greatly between patients, with some people responding poorly to this biguanide. Because of the well known therapeutic inertia with respect to pharmacological treatment of diabetes, insufficient glucose control might persist for a long time before any treatment adjustment is made in people who respond poorly to metformin monotherapy.
Disciplines :
Pharmacy, pharmacology & toxicology
Endocrinology, metabolism & nutrition
Author, co-author :
SCHEEN, André  ;  Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
Language :
English
Title :
Personalising metformin therapy: a clinician's perspective
Publication date :
2014
Journal title :
The Lancet Diabetes and Endocrinology
ISSN :
2213-8587
eISSN :
2213-8595
Publisher :
Elsevier
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 19 March 2014

Statistics


Number of views
131 (4 by ULiège)
Number of downloads
538 (1 by ULiège)

Scopus citations®
 
10
Scopus citations®
without self-citations
5
OpenCitations
 
7

Bibliography


Similar publications



Contact ORBi